Cargando…

Guidelines for the use and management of long-acting injectable antipsychotics in serious mental illness

BACKGROUND: Long-acting injectable (LAI) formulations are not widely used in routine practice even though they offer advantages in terms of relapse prevention. As part of a process to improve the quality of care, the French Association for Biological Psychiatry and Neuropsychopharmacology (AFPBN) el...

Descripción completa

Detalles Bibliográficos
Autores principales:	Llorca, Pierre Michel, Abbar, Mocrane, Courtet, Philippe, Guillaume, Sebastien, Lancrenon, Sylvie, Samalin, Ludovic
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3898013/ https://www.ncbi.nlm.nih.gov/pubmed/24359031 http://dx.doi.org/10.1186/1471-244X-13-340

Ejemplares similares

Clinical Decision-Making in the Treatment of Schizophrenia: Focus on Long-Acting Injectable Antipsychotics
por: Samalin, Ludovic, et al.
Publicado: (2016)

Ketamine for the acute treatment of severe suicidal ideation: double blind, randomised placebo controlled trial
por: Abbar, Mocrane, et al.
Publicado: (2022)

Patient perspectives on use of long-acting antipsychotics in bipolar disorder: focus on risperidone injection
por: Samalin, L, et al.
Publicado: (2010)

The Use of Long-Acting Injectable Antipsychotics (LAI) in the Serious Mental Illness (SMI) Patients Enrolled in an Assertive Community Treatment (ACT) Program
por: Yee, Maria Ruiza, et al.
Publicado: (2021)

Cost Effectiveness of Paliperidone Long-Acting Injectable Versus Other Antipsychotics for the Maintenance Treatment of Schizophrenia in France
por: Druais, Sylvain, et al.
Publicado: (2016)

Controversies Surrounding the Use of Long-Acting Injectable Antipsychotic Medications for the Treatment of Patients with Schizophrenia
por: Kane, John M., et al.
Publicado: (2021)

Development and Calibration of the PREMIUM Item Bank for Measuring Respect and Dignity for Patients with Severe Mental Illness
por: Fernandes, Sara, et al.
Publicado: (2022)

Group Post-Admission Cognitive Therapy for Suicidality vs Individual Supportive Therapy for the prevention of repeat suicide attempts: a randomized controlled trial
por: Chaïb, Laurent S., et al.
Publicado: (2020)

Mental health pharmacists views on shared decision-making for antipsychotics in serious mental illness
por: Younas, Mediha, et al.
Publicado: (2016)

Clinical potential of lurasidone in the management of schizophrenia
por: Samalin, Ludovic, et al.
Publicado: (2011)

Cardiovascular risk screening of patients with serious mental illness or use of antipsychotics in family practice
por: Jakobs, Kirsti M., et al.
Publicado: (2020)

Exploratory analysis of the French version of the beliefs about medicines questionnaire in patients with severe mental disorders: Factorial structure and reliability in specific populations of schizophrenic, bipolar and depressive patients
por: Samalin, Ludovic, et al.
Publicado: (2017)

The Use of Long-Acting Injectable Antipsychotics in Schizophrenia
por: Miyamoto, Seiya, et al.
Publicado: (2017)

Attitudes of European physicians towards the use of long-acting injectable antipsychotics
por: Patel, Maxine X., et al.
Publicado: (2020)

Antipsychotic Medication Adherence and Healthcare Services Utilization in Two Cohorts of Patients with Serious Mental Illness
por: Forma, Felicia, et al.
Publicado: (2020)

Comparison of Efficacy and Safety between Long-Acting Injectable Antipsychotic Monotherapy and Combination of Long-Acting Injectable and Oral Antipsychotics in Patients with Schizophrenia
por: Sathienluckana, Thanompong, et al.
Publicado: (2021)

Clinical and economic impact of long-acting injectable antipsychotics in patients previously treated with short-acting oral antipsychotics
por: Kheloussi, Steven, et al.
Publicado: (2022)

Long-Acting Injectable Antipsychotics in First-Episode Schizophrenia
por: Parellada, Eduard, et al.
Publicado: (2012)

Long-acting injectable antipsychotics: focus on olanzapine pamoate
por: Lindenmayer, JP
Publicado: (2010)

Long-acting Injectable Antipsychotics in First-episode Schizophrenia
por: Jeong, Hyun-Ghang, et al.
Publicado: (2013)

Population pharmacokinetics and dosing of long-acting injectable antipsychotics
por: Kim, David D., et al.
Publicado: (2021)

Long-acting injectable antipsychotics during pregnancy: An update
por: Paraschakis, A., et al.
Publicado: (2021)

The place of long-acting injectable antipsychotics in the treatment of schizophrenia
por: Kane, John M., et al.
Publicado: (2023)

Using A Pharmacy-Based Intervention To Improve Antipsychotic Adherence Among Patients With Serious Mental Illness
por: Valenstein, Marcia, et al.
Publicado: (2011)

Time to Rehospitalization in Patients With Schizophrenia Receiving Long-Acting Injectable Antipsychotics or Oral Antipsychotics
por: Lin, Ching-Hua, et al.
Publicado: (2019)

Management of Schizophrenia with Long-Acting Injectable Antipsychotic Medications: An Assessment of the Educational Needs of Clinicians
por: Citrome, Leslie, et al.
Publicado: (2022)

Efficacy of shared decision-making on treatment adherence of patients with bipolar disorder: a cluster randomized trial (ShareD-BD)
por: Samalin, L., et al.
Publicado: (2018)

Beliefs about antipsychotic versus hypoglycemic medications among individuals with serious mental illness and type 2 diabetes
por: Aakre, Jennifer M, et al.
Publicado: (2012)

Long Acting Injectable Antipsychotics in the Treatment of Schizophrenia and Bipolar Disorder
por: DEVRİMCİ ÖZGÜVEN, Halise, et al.
Publicado: (2021)

Review of Pharmacokinetics and Pharmacogenetics in Atypical Long-Acting Injectable Antipsychotics
por: Toja-Camba, Francisco José, et al.
Publicado: (2021)

Pharmacokinetic Characteristics of Long-Acting Injectable Antipsychotics for Schizophrenia: An Overview
por: Correll, Christoph U., et al.
Publicado: (2021)

The use of long-acting injectable antipsychotics in an acute psychiatric unit
por: Ortega-Hernández, G., et al.
Publicado: (2023)

Positive views on antipsychotic long-acting injections: results of a survey of community patients prescribed antipsychotics
por: Mace, Shubhra, et al.
Publicado: (2019)

T213. TREND OF LONG-ACTING INJECTABLE ANTIPSYCHOTICS USE IN ASIA: FINDINGS FROM REAP ANTIPSYCHOTIC STUDIES
por: Lin, Shih-Ku, et al.
Publicado: (2020)

Risperidone long-acting injection in Schizophrenia Spectrum Illnesses compared to first generation depot antipsychotics in an outpatient setting in Canada
por: Lammers, Laura, et al.
Publicado: (2013)

Patient and Health Care Provider Perspectives on Long Acting Injectable Antipsychotics in Schizophrenia and the Introduction of Olanzapine Long-Acting Injection
por: Wehring, Heidi J., et al.
Publicado: (2011)

Long-Acting Injectable Antipsychotics for First-Episode Schizophrenia: The Pros and Cons
por: Kim, Borah, et al.
Publicado: (2012)

Patients’ experiences of long-acting injectable antipsychotics: a qualitative study
por: Chiu, Lin-Ling, et al.
Publicado: (2019)

Tachycardia in patients treated with clozapine versus antipsychotic long-acting injections
por: Nilsson, Björn M., et al.
Publicado: (2017)

Rating Opportunity for Long-Acting Injectable Antipsychotic Initiation Index (ROLIN)
por: Ifteni, Petru, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_mtnj92j88srgudgslorfg0cp4i